Hadassah

Granalix BioTechnologies Introduces Food Additive to Protect Against Neurodegenerative Disease

Monday, Nov 14 2016

Prof. Ruth Gabizon with neurology research colleagues.

Granalix BioTechnologies, whose founder and Chief Executive Officer is Hadassah Medical Organization Experimental Neurologist Prof. Ruth Gabizon, has launched a food supplement containing pomegranate oil that has proven to protect against neurodegenerative diseases in pre-clinical models.

Called GranaGard™, the supplement is a submicron Pomegranate Seed Oil (PSO) emulsion, and is an innovative formulation of one of the strongest natural antioxidants, Punicic acid (an Omega 5 lipid). The patented formulation has been shown to delay disease onset and prevent neuronal death in a model of genetic prion disease (a neurodegenerative disease caused by a mutation that leads to misfolded prion proteins which, in turn, kill off normal brain cells). The formulation also has been shown to reduce disease burden in a mouse model of Multiple Sclerosis. In both models, there was no evidence of toxicity after long-term administration.

As Prof. Gabizon explains: "Reactive oxygen species (ROS) are chemically active molecules that can lead to significant damage to cells, particularly in the central nervous system (CNS). It is therefore widely accepted that this chemical agent contributes to chronic inflammation and neurodegenerative diseases. While antioxidants that can counteract ROS are ubiquitously present in a healthy human diet, their activity is limited by chemical degradation, poor bioavailability, reduced distribution to the CNS, and sub-pharmacological doses.”

To overcome these limitations, Prof. Gabizon relates, she and her research team created GranaGard. “In addition to its protective role in subjects at risk of developing neurodegenerative conditions,” she says, “GranaGard is expected to be effective for general neurological well-being for the larger public.” 

Company spokespeople explain that the PSO submicron droplets have the advantage that the nanoformulation may avoid the first passage of the oil through the liver, thereby enhancing the availability of the droplets to other organs such as the CNS where it is then able to enter the brain and protect membrane lipids from ROS attacks that occur as a result of both every-day efforts and pathological events.

Granalix BioTechnologies focuses on developing science-based novel formulations of natural antioxidants that can be used to prevent and treat neurodegenerative conditions. The Company was established in 2014 by Prof. Gabizon and Prof. Shlomo Magdassi of the Casali Center for Applied Chemistry, the Institute of Chemistry, and the Center for Nanoscience and Nanotechnology at the Hebrew University. It is a spinoff of the Hebrew University’s technology transfer company, Yissum, and Hadasit, Hadassah’s technology transfer company.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Nov 30 2016

Hadassah Opens Israel’s First Heart Valve Disease Clinic

The Hadassah Medical Organization has opened Israel’s first Heart Valve Disease Clinic, which is geared toward detecting and treating the most complicated cases of heart valve disease--a growing problem in an aging population.

READ MORE ›
alt_text

Wednesday, Nov 30 2016

Hadassah Volunteers of 27 Years Blessed with Daughter After 30 Years of Waiting

For 27 years, Rabbi Yitzchak and Sima Peretz have volunteered at the Hadassah Medical Organization, arranging and preparing meals and sleeping arrangements for families of patients; now, they, after 30 years of waiting, have been blessed with a child of their own--born at Hadassah.

READ MORE ›
alt_text

Wednesday, Nov 30 2016

Hadassah Teams Up with Spinal Cord Institute to Study Outcomes of Traumatic Injuries

The medical interventions and outcomes for Israelis with a spinal cord injury (SCI) will now be captured in the Rick Hansen SCI Registry (RHSCIR), thanks to the November 16th launch of a partnership between the Hadassah Medical Organization and the Rick Hansen Institute (RHI), a Canadian-based not-for-profit organization named after the paralympic athlete who suffered a severe spinal cord injury following a car accident.

READ MORE ›

Tuesday, Nov 29 2016

Hadassah Calls for Improvements, Careful Review of 21st Century Cures

Last week, congressional leadership revived negotiations for the 21st Century Cures and Innovation for Healthier Americans legislation, which lack crucial provisions to protect female patients. The House is expected to hold limited debate and a vote, without opportunity for amendments, later this week.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More